Publicaciones en las que colabora con José Ignacio Riezu Boj (55)

2023

  1. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

  2. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

2021

  1. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study

    European Journal of Nutrition, Vol. 60, Núm. 6, pp. 3043-3057

  2. Three different genetic risk scores based on fatty liver index, magnetic resonance imaging and lipidomic for a nutrigenetic personalized management of nafld: The fatty liver in obesity study

    Diagnostics, Vol. 11, Núm. 6

2020

  1. Association of the SH2B1 RS7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease

    Nutrients, Vol. 12, Núm. 5

2019

  1. Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: A comparison with healthy controls

    Nutrients, Vol. 11, Núm. 2

2017

  1. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy

    Cancer Research, Vol. 77, Núm. 13, pp. 3672-3684

2016

  1. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

  3. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming

    Journal of Immunology, Vol. 193, Núm. 3, pp. 1151-1161

  3. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Usage of Adenovirus Expressing Thymidine Kinase Mediated Hepatocellular Damage for Enabling Mouse Liver Repopulation with Allogenic or Xenogenic Hepatocytes

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683

  2. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  3. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483